Biodesix, Inc. (BDSX)

Market Cap	131.31M +8.3%
Revenue (ttm)	88.50M +24.1%
Net Income	-35.27M
EPS	-4.67
Shares Out	9.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,519
Open	14.07
Previous Close	14.25
Day's Range	12.78 - 14.40
52-Week Range	3.44 - 20.21
Beta	0.57
Analysts	Strong Buy
Price Target	32.50 (+143.99%)
Earnings Date	May 12, 2026

About BDSX

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 28, 2020
• Employees: 334
• Stock Exchange: NASDAQ
• Ticker Symbol: BDSX
• Website: https://www.biodesix.com

Financial Performance

In 2025, Biodesix's revenue was $88.50 million, an increase of 24.08% compared to the previous year's $71.32 million. Losses were -$35.27 million, -17.86% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 143.99% from the latest price.

Price Target

$32.5

(143.99% upside)

Analyst Consensus: Strong Buy